Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,”...
Kite, a Gilead Science Inc (NASDAQ: GILD) company, announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically...
-- Landmark ZUMA-7 Study OS Data Reach Maturity Per Protocol, 5 Years After 1st Patient Randomized -- Kite, a Gilead Company (Nasdaq: NASDAQ:GILD), today announced the primary...
-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee -- FOSTER...
Looking for a clear three wave move in wave (ii) to then place longs.
Stocks surged in July, with the major indexes enjoying their best gains since 2020. But the market is still off substantially for the year. The rally came despite the Federal...
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Average | 91.23 (+15.83% Upside) |
| High | 115.00 |
| Low | 77.00 |
| Price | 78.76 |
| No. of Analysts | 26 |
Type | Daily | Weekly | Monthly |
|---|---|---|---|
| Moving Averages | |||
| Technical Indicators | |||
| Summary |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 153.40 | 155.40 | 153.00 | -0.40 | -0.26% | 5.22M | London | |||
| 220.00 | 223.00 | 218.00 | 0.00 | 0.00% | 710.01K | London | |||
| 139.78 | 144.40 | 139.64 | -2.88 | -2.02% | 75.55M | London | |||
| 225.00 | 232.00 | 222.00 | +22.00 | +10.84% | 842.54K | London | |||
| 104.75 | 105.65 | 102.70 | +1.55 | +1.50% | 19.51M | London | |||
| 1,030.00 | 1,030.00 | 1,030.00 | -5.00 | -0.48% | 8.21K | London | |||
| 1,140.00 | 1,152.00 | 1,108.00 | +14.00 | +1.24% | 472.18K | London | |||
| 490.50 | 493.00 | 476.50 | +7.50 | +1.55% | 92.17K | London | |||
| 0.136 | 0.1395 | 0.136 | -0.0050 | -3.57% | 176.00M | London | |||
| 12.00 | 12.00 | 12.00 | +0.30 | +2.56% | 528.65K | London | |||
| 90.80 | 91.51 | 90.50 | -0.58 | -0.64% | 305.79M | London | |||
| 365.00 | 360.00 | 358.00 | +4.00 | +1.11% | 280.31K | London | |||
| 0.12 | 0.13 | 0.13 | 0.00 | 0.00% | 0.00 | Aquis Exchange | |||
| 273.30 | 284.50 | 271.30 | +2.80 | +1.03% | 1.51M | London | |||
| 92.40 | 92.40 | 92.40 | +2.00 | +2.20% | 218.90K | London |